Metabolic alterations underlying Bevacizumab therapy in glioblastoma cells

Anti-VEGF therapy with Bevacizumab is approved for glioblastoma treatment, however, it is known that tumors acquired resistance and eventually became even more aggressive and infiltrative after treatment. In the present study we aimed to unravel the potential cellular mechanisms of resistance to Bev...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Oncotarget
Hlavní autoři: Miranda-Gonçalves, Vera, Cardoso-Carneiro, Diana, Valbom, Inês, Cury, Fernanda Paula, Silva, Viviane Aline, Granja, Sara, Reis, Rui M., Baltazar, Fátima, Martinho, Olga
Médium: Artigo
Jazyk:Inglês
Vydáno: Impact Journals LLC 2017
Témata:
Research Paper
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC5732757/
https://ncbi.nlm.nih.gov/pubmed/29262591
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.21761
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky